Von Willebrand disease type 2A

Von Willebrand disease type 2A (VWD type 2A) is a qualitative variant of von Willebrand disease characterized by a decreased ability of von Willebrand factor (VWF) to bind to platelets and subendothelial collagen due to a selective deficiency of high-molecular-weight VWF multimers. It is the most common subtype of type 2 VWD. The condition primarily affects the blood's ability to clot properly, as VWF plays a critical role in platelet adhesion and as a carrier protein for coagulation factor VIII. The loss of large multimers results in impaired platelet-dependent hemostasis. Patients with VWD type 2A typically present with mucocutaneous bleeding symptoms, including easy bruising, prolonged bleeding from cuts or dental procedures, epistaxis (nosebleeds), menorrhagia (heavy menstrual bleeding) in women, and excessive bleeding after surgery or trauma. Gastrointestinal bleeding may also occur. Symptoms can range from mild to moderate in severity and may first become apparent in childhood or later in life, often triggered by surgical or dental procedures. Laboratory findings characteristically show a disproportionate reduction in VWF ristocetin cofactor activity (VWF:RCo) relative to VWF antigen levels, along with an abnormal multimer pattern showing absence of large and intermediate multimers. Treatment of VWD type 2A focuses on preventing and managing bleeding episodes. Desmopressin (DDAVP), which stimulates release of VWF from endothelial cells, may provide a transient response in some patients but is often less effective than in type 1 VWD because the released VWF still lacks normal large multimers and may be rapidly cleared. Therefore, VWF-containing plasma-derived factor concentrates (such as Humate-P or Alphanate) are the mainstay of treatment, particularly for significant bleeding or surgical prophylaxis. Antifibrinolytic agents such as tranexamic acid or aminocaproic acid may be used as adjunctive therapy, especially for mucosal bleeding. Hormonal therapies can help manage menorrhagia in affected women. Patients should avoid antiplatelet medications such as aspirin and should be managed in consultation with a hematologist experienced in bleeding disorders.

Common questions about Von Willebrand disease type 2A